IGF-IR peptide vaccine

IGF-IR peptide vaccine (also referred to as IGF-1R peptide vaccine) is an immunotherapeutic cancer vaccine consisting of peptide epitopes derived from the insulin-like growth factor 1 receptor (IGF-1R). IGF-1R is a receptor tyrosine kinase overexpressed in various malignancies, including breast, ovarian, and pancreatic cancers, where it promotes cell survival, proliferation, and resistance to therapy. The vaccine is designed to stimulate antigen-specific immune responses, primarily CD4+ T-helper 1 (Th1) or B-cell mediated immunity, targeting tumor cells that overexpress IGF-1R. Preclinical and clinical development has been pursued by academic institutions, including the University of Washington (under Dr. Mary L. Disis) and Ohio State University, both as a monotherapy and as a component of multi-antigen vaccines (such as TNBCvax or TAVac) for the prevention and treatment of breast and other solid tumors.

Other names

IGF-1R peptide vaccineIGF1R peptide vaccineIGF 1R peptide vaccineinsulin-like growth factor-1 receptor peptide vaccineinsulin-like growth factor-I receptor peptide vaccine